Chemours Co. CC 深 沪
等待开盘 07-01 09:30:00 美东时间
20.52
+0.260
+1.28%
华盛通- 最 高20.705
- 今 开20.34
- 成交量 309.22万股
- 最 低 19.83
- 昨 收 20.26
- 总市值 30.86亿
- 52周最高 28.5825
- 市盈率 静 --
- 换手率 2.06%
- 52周最低 10.265
- 委 比 -50.00%
- 总股本 1.50亿
- 历史最高 50.5225
- 量 比 0.73
- 振 幅 4.32%
- 历史最低 -4.7075
- 每 手 1
- 风险率 4.33%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Mizuho Maintains Outperform on Chemours, Lowers Price Target to $25
Mizuho analyst John Roberts maintains Chemours (NYSE:CC) with a Outperform and lowers the price target from $30 to $25.
30分钟前
摩根大通将Chemours目标股价上调至22美元 上涨潜力达25.65%
核心事件：两家机构同步上调科慕（Chemours，股票代码CC）目标价，科慕主营钛技术产品、氟化物产品、化工解决方案，核心产品包括氢燃料电池与电解槽应用的Na...
06-26 09:56
Chemours Reaches Major PFAS Settlement and Compliance Agreement
Chemours Company ( ($CC) ) just unveiled an announcement. On June 23, 2026, Che...
06-24 23:17
U.S. Department Of Justice Announces Chemours Agrees To Pay $450M Settlement Charges Over Alleged Release Of Per- And Polyfluoroalkyl Substances In Three States
https://www.justice.gov/opa/pr/chemours-agrees-450m-landmark-settlement-agreement-releases-pfas-forever-chemicals-west
06-24 22:44
Chemours Reaches Agreement with U.S. EPA to Resolve Claims Relating to PFAS
The settlement resolves the federal government's claims relating to discharge of PFAS compounds across three current operating sites, as well as certain environmental claims by the State of ...
06-24 22:43
Justice Department says Chemours agreed to $450 million settlement agreement
Justice Department says Chemours agreed to $450 million settlement agreement WASHINGTON, June 24 (Reuters) - The U.S. Department of Justice said on Wednesday that The Chemours Company agreed to a $450 million settlement over the release of "forever chemicals" in West Virginia, North Carolina and New
06-24 22:33
美股大行评级 | 英伟达绩后获11家大行集体上调目标价；劳氏、ELF、Intuit、VF等惨遭多家大行下调目标价
今日重点评级关注：康托·菲茨杰拉德：维持Ultragenyx药业"超配"评级，目标价从84美元升至96美元；Ascendiant Capital：维持Liqtech国际"买入"评级，目标价从4.3美元升至4.4美元
05-22 10:18
JP Morgan Maintains Neutral on Chemours, Raises Price Target to $22
JP Morgan analyst Jeffrey Zekauskas maintains Chemours (NYSE:CC) with a Neutral and raises the price target from $17 to $22.
05-22 03:54
Chemours Lawsuit Dismissed as Court Finds Investors Failed to Plead Misleading Statements
A Delaware federal judge dismissed the securities lawsuit against The Chemours ...
05-22 03:14
